Nano Med Tech Reveal New Cancer Treatment Technology at U.S. Nanotech Conference

FOR IMMEDIATE RELEASE
Anaheim, California, United States of America (Free-Press-Release.com) January 17, 2012 -- New Nanotechnology is working in conjunction with T-cell biology to produce diagnostics and treatments that bypass the immune system and deliver localized therapy, which, through their extremely accurate targeting, all but eliminate negative side effects.

At the recent Nanotech Expo in California, academic and industry researchers clarified some of the advances that are at the forefront of the new technology, including T-cell based delivery systems, which would give scientists the ability to design nanoparticles’ function and precise targeting.

Nano Med Tech, a Chinese company, has been steadily progressing on a high-throughput microelectroporation device to transfer RNA species in order to redirect the specificity of T-cells.

The machine is being designed specifically to electro-transfer functionalized nanoparticles to enhance T-cell biology. This configuration produces T cells that can respond both rapidly and effectively as drug-delivery vehicles, thus having remarkable potential as a tumor-specific immunotherapy.

“We see T cells as a vehicle for targeted delivery of nanoparticles to tissue sites,” said Nano Med Tech’s Charles Lee. “In the typical case the endothelial system will filter infused nanoparticles. But with this new process, the nanoparticles in T cells prevent rejection. The scientist at Nano Med Tech developed this device specifically to make repeated infusions of these nano-modified T cells possible.”


Lee went on to stress the fact that, “This is far superior to older procedures in which therapeutic genes were introduced through the injection of viruses. The nanoparticle component of this treatment is able to greatly boost both effectiveness and, in the case of diagnostic usage, imaging. In our clinical studies, this procedure has been remarkably more effective than older treatments in dealing with malignant tumors.”